Introduction of MMS to Antenatal Care in Bamako, Mali
Launched by JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH · Mar 25, 2022
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
In the past several decades, the République du Mali (Mali) has achieved reductions in both maternal mortality ratio and neonatal mortality rate. However, with an estimated 562 maternal deaths per 100,000 live births and 65.8 infant deaths per 1,000 births, substantial changes to maternal child health services will likely need to be implemented to realize the benefits of universal healthcare for mothers and children and recover from the damaging impacts of colonialism and conflict. The prevalence of low birth weight (\<2.5 kg) among children whose birth weights are known is estimated to be a...
Gender
ALL
Eligibility criteria
- INCLUSION CRITERIA:
- • Sample Group 1: Pregnant Women
- Potential supplementation trial participants must meet all the following criteria to be eligible for inclusion in the study:
- • 1. Age 18 years or older at screening.
- • 2. At time of enrollment, able and willing to comply with all study requirements and complete all study procedures.
- • 3. Able and willing to provide verbal informed consent to be screened for and to take part in the study.
- • 4. Intention to stay within study catchment area for study duration and willingness to give adequate locator information, as defined in site standard operating procedures (SOPs).
- • 5. Presenting for first ANC visit.
- 6. Pregnant, as confirmed by at least one of the following:
- • 1. Uterine examination
- • 2. Urine human chorionic gonadotropin (HCG)
- • 3. Ultrasound
- • Sample Group 2: Midwives
- • Midwives who participated in delivery of the intervention will be recruited from the six health center study sites. Inclusion criteria includes the provision of verbal informed consent.
- • Sample Group 3: Pharmacists
- • Pharmacists who participated in delivery of the intervention will be recruited from the six health center study sites. Inclusion criteria includes the provision of verbal informed consent.
- • Sample Group 4: Family Members
- • Family members (e.g., male partners and mothers/mothers-in-law) will be recruited based on participation of their female family member in the study protocol. Inclusion criteria includes the provision of verbal informed consent.
- EXCLUSION CRITERIA:
- • Sample Group 1: Pregnant Women
- Potential supplementation trial participants who meet any of the following criteria will be excluded from the study:
- • 1. At time of enrollment, evidence of gestational age greater than 26 0/7 weeks, using one or more of the following methods: a) Uterine examination, b) First day of last normal menstrual period, and c) Ultrasound
- • 2. As determined by the site investigator, any significant uncontrolled active or chronic cardiovascular, renal, liver, hematologic, neurologic, gastrointestinal, psychiatric, endocrine, respiratory, immunologic disorder, or infectious disease. Note: examples of uncontrolled conditions include but are not limited to the following: HIV not virally suppressed, COVID-19 infection, symptomatic malaria infection.
- • 3. Has any other condition that, in the opinion of the site investigator, would preclude verbal informed consent, make study participation unsafe, complicate interpretation of study outcome data, or otherwise interfere with achieving the study objectives.
- • 4. At time of enrollment, any known condition requiring routine antenatal care to take place at a location other than the study site CSCOM, e.g., Rh- negative status.
- • 5. At enrollment, reports either of the following: a) Participation in any research study involving drugs, vaccines, or medical devices during the current pregnancy, b) Expected to participate in other research studies involving drugs, vaccines, or medical devices for the duration of study participation
- • Sample Group 2: Midwives
- • Potential participants who do not provide verbal informed consent will not be included.
- • Sample Group 3: Pharmacists
- • Potential participants who do not provide verbal informed consent will not be included.
- • Sample Group 4: Family Members
- • Potential participants who do not provide verbal informed consent will not be included.
About Johns Hopkins Bloomberg School Of Public Health
The Johns Hopkins Bloomberg School of Public Health is a leading institution dedicated to advancing public health research and education. Renowned for its rigorous academic programs and commitment to improving global health outcomes, the School conducts innovative clinical trials that address pressing health challenges. With a focus on evidence-based practices, multidisciplinary collaboration, and community engagement, the Bloomberg School leverages its extensive resources and expertise to contribute to the development of effective public health interventions and policies. Through its research endeavors, the School aims to enhance population health and inform health policy both locally and globally.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Bamako, , Mali
Patients applied
Trial Officials
Kristen M Hurley, PhD
Principal Investigator
Johns Hopkins Bloomberg School of Public Health
Lisa Noguchi, PhD
Study Director
Jhpiego
Samba Sow, MD
Study Director
Center for Vaccine Development - Mali
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials